Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Barriers and facilitators of cardiovascular disease prevention services for women with prior gestational diabetes or hypertensive disorders of pregnancy: a scoping review
Quansah, Dan Yedu , Visintini, Sarah , Kim, Helena, Harris, Laura, Dai, Nini , O’Neill, Carley , Savard, Karine, Coutinho, Thais , Mullen, Kerri‐Anne, Coutinho, Thais D. , Ahmed, S. Faisal , Dai, Nichole, Savard, Karine, Mir, Hassan R.

Mayo Clinic

European Journal of Preventive Cardiology | July 15, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurjpc/zwaf435 | PMID 40694664 Get It

Abstract Aims Although cardiovascular disease (CVD) screening and preventive care in the early postpartum are recommended for women with prior gestational diabetes (GDM) and hypertensive disorders of pregnancy (HDP), certain barriers limit access to such services. We conducted a scoping review to summarize evidence on the barriers and facilitators of CVD prevention services among women with prior GDM or HDP. Methods and results A comprehensive search strategy was used to search articles published in three databases (Ovid Medline, CINAHL, Embase). Studies published in English or French that investigated and reported barriers or facilitators to postpartum CVD screening and preventive care among women with previous GDM and HDP were included. Out of 18 565 studies we screened, 29 studies (12 qualitative, 17 quantitative) were included. Main individual level barriers including lack of knowledge, health, and emotional factors were identified. Competing priorities, lack of family/friend support, and mistrust of healthcare providers were the most reported interpersonal level barriers, while gaps in communication were the most significant organizational barrier, and gaps in insurance coverage was the most reported system barrier. Individual level facilitators included a personal desire for better health and availability of postpartum programmes, and the most reported interpersonal facilitator was women's commitment to modelling a healthy lifestyle for their children. Organizational level facilitators were access to primary care providers and follow-up visit reminders, and programme availability in native languages. Conclusion Women with prior GDM or HDP face significant barriers to accessing postpartum CVD prevention services. These barriers ranged from individual-level knowledge gaps to system-level healthcare disparities.
Lymphocyte Kinetics and Outcomes of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma With Out of Specification Products
Dingli, Sarah , Rothweiler, Paul , Binder, Moritz , Cook, Joselle , Gertz, Morie A. , Hayman, Suzanne R. , Kapoor, Prashant , Kourelis, Taxiarchis , Kumar, Shaji , Warsame, Rahma , Lin, Yi , Erdman, Arthur G. , Dingli, David , Kumar, Shaji K , Warsame, Rahma , Dingli, David , Gertz, Morie A , Binder, Moritz , Cook, Joselle M , Siddiqui, Mustaqeem

Mayo Clinic

American Journal of Hematology | July 15, 2025 | Volume: 100 | Issue: 9 | Pages: 1705-1708

10.1002/ajh.70001 | PMID 40662471 Get It

Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report
Al‐Samkari, Hanny , Kasthuri, Raj S. , Mager, Hans‐Jurgen, Zhou, Jenny Y. , Serra, Marcelo M. , Samuelson‐Bannow, Bethany T., Doren, Layla N Van , Piccirillo, Jay F. , Clancy, Marianne S. , Thomas, Sonia , Riera‐Mestre, Antoni , Gossage, James R. , Hermans, Cédric , Hammill, Adrienne M. , Drygalski, Annette von , Olitsky, Scott E., Faughnan, Marie E. , Sewaralthahab, Sarah , Iyer, Vivek N , Al-Samkari, Hanny , Hammill, Adrienne , Kasthuri, Raj S , Thomas, Sonia M , McCrae, Keith R. , Pishko, Allyson M. , Iyer, Vivek , Winship, Ingrid , Mei‐Zahav, Meir

Mayo Clinic

American Journal of Hematology | July 15, 2025 | Volume: 100 | Issue: 10 | Pages: 1813-1827

10.1002/ajh.70011 | PMID 40662351 Get It

ABSTRACT Hereditary hemorrhagic telangiectasia (HHT, Osler‐Weber‐Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease‐modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies. However, the lack of consensus on standardized severity definitions, outcome criteria, and terminology remains a major obstacle to clinical investigation and therapeutic development in HHT. Additionally, with the ongoing repurposing of antiangiogenic agents and emerging development of novel HHT‐specific therapies, comparative clinical trials are expected in the future. Therefore, to end the problematic heterogeneity hindering these efforts, the Global Research and Medical Advisory Board (GRMAB) of the Cure HHT Foundation, an international group of recognized HHT experts, convened a conference of expert HHT clinician‐investigators from within GRMAB as well as invited external experts in HHT and bleeding disorders generally, patients with HHT, and patient advocates to define standard terminology and definitions for outcomes and severity classification for bleeding and anemia in HHT. These criteria and definitions should be adopted by regulators, investigators, and the pharmaceutical industry in the development and performance of interventional clinical trials and cohort studies to allow improved comparability between clinical trials, facilitate communication between clinicians and investigators, improve therapeutic guideline development, and provide a standardized framework for regulatory agencies. Search Strategy and Selection Criteria Evidence for this report was systematically identified and evaluated utilizing two search strategies in Ovid MEDLINE, described in full detail in the Appendix, pp.4–13. The searches were conducted on January 7, 2025. The titles and abstracts of each record were reviewed, and the inclusion criteria were applied to all search results to identify full text articles to be retrieved for further review. All retrieved full texts were then reviewed to reach a final determination if a study met the inclusion criteria. Included references were then compiled into evidence tables, which were then utilized by the International Consensus Report Working Group throughout the development of report recommendations.
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial
Chen, Charles D., Jack, Clifford R. , Koeppe, Robert, Hornbeck, Russ C. , Koudelis, Deborah, Keefe, Sarah , Aggarwal, Neelum T. , Bird, Thomas D. , Black, Sandra E., Chhatwal, Jasmeer P. , Day, Gregory S. , Farlow, Martin R. , Gauthier, Serge , Honig, Lawrence S., Xiong, Chengjie , Masellis, Mario, Méndez, Patricio Chrem, Ringman, John M. , Snider, B. Joy, Salloway, Stephen, Dyck, Christopher H. van , Klein, Gregory , Clifford, David B. , Hassenstab, Jason , Mills, Susan L., Perrin, Richard J., Supnet, Charlene , Wang, Guoqiao , Xiong, Chengjie , Team, for the DIAN‐TU Study, Jack, Clifford R , Day, Gregory S , Xiong, Chengjie , Chen, Charles D , Hassenstab, Jason , Supnet-Bell, Charlene , McCullough, Austin , Gordon, Brian A. , Joseph‐Mathurin, Nelly , McKay, Nicole S. , Hobbs, Diana A. , Flores, Shaney , Allegri, Ricardo , Berman, Sarah , Black, Sandra E. , Brooks, William S. , Fox, Nick C. , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Jucker, Mathias , Masters, Colin L. , Schofield, Peter R. , Shimada, Hiroyuki , Suzuki, Kazushi , Cruchaga, Carlos , Li, Yan , McDade, Eric , Morris, John C. , Bateman, Randall J. , Benzinger, Tammie L.S. , Team, for the DIAN‐TU Study

Mayo Clinic

Alzheimer's & Dementia | July 15, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70347 | PMID 40660741 Get It

Abstract INTRODUCTION Monoclonal anti‐amyloid therapies are now accessible, but how these treatments influence changes within the brain is still not clear. We investigated overall and regional change in amyloid removal, glucose metabolism, and atrophy in trial participants with dominantly inherited Alzheimer's disease (DIAD). METHODS In the DIAN‐TU‐001 trial, 92 carriers received gantenerumab or placebo and underwent serial neuroimaging assessments including [ 11 C]‐Pittsburgh compound‐B (PiB) positron emission tomography (PET), [ 18 F]‐fluoro‐2‐deoxyglucose (FDG) PET, and magnetic resonance imaging (MRI). RESULTS Gantenerumab significantly reduced PiB‐PET uptake overall and in most regions and showed no changes in FDG‐PET or MRI measures. Drug effects were associated with baseline PiB‐PET uptake, and the largest effects occurred in medial regions. DISCUSSION Treated DIAD participants, and especially those with higher amyloid burden, showed a decrease in PiB‐PET uptake, which was more pronounced in the basal ganglia and medial frontal structures. These results may inform patient response and future drug trial design. Highlights Gantenerumab unevenly decreased Aβ burden as measured by PiB‐PET across brain regions. The strongest decrease in PiB‐PET uptake was in basal ganglia and medial frontal structures. Variable drug effect on Aβ was partly due to the amount of burden present before treatment. There was no regional effect on FDG‐PET metabolism or MRI volumetrics after 4 years.
E-122 Endovascular rodent model using tail access and ultrasound guidance
Lortscher, Sarah, Bayraktar, Evren , Oliver, A, Brinjikji, W, Kadirvel, R, Kallmes, D, Ognard, Julien , Hajj, G El , Ding, Yonghong , Brinjikji, W, Kadirvel, Ramanathan , Kallmes, David F.

Mayo Clinic

SNIS 22nd annual meeting electronic poster abstracts | July 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: A173.2-A174

10.1136/jnis-2025-snis.238 Get It

E-060 The rabbit superior mesenteric artery as an in vivo model for perforator artery occlusion assessment after flow diversion
Cortese, Jonathan, Lortscher, Sarah, Kallmes, David F. , Kadirvel, Ramanathan , Cortese, Jonathan , Bayraktar, E, Dai, Daying , Ognard, Julien , Zarrintan, Armin , Hajj, G El , Ghozy, Sherief , Ding, Yonghong

Mayo Clinic

SNIS 22nd annual meeting electronic poster abstracts | July 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: A132.2-A133

10.1136/jnis-2025-snis.176 Get It

Brain atrophy patterns in anti-IgLON5 disease
Yogeshwar, Selina , Bartels, Frederik , Muñiz‐Castrillo, Sergio , Picard, Géraldine , Bernard, E , Ζεκερίδου, Αναστασία , Ringelstein, Marius , Kraft, Andrea , Kovac, Stjepana , Wandinger, Klaus‐Peter , Vries, Juna M. de, Boon, Agnita J.W. , Veenbergen, Sharon , Penner, Loana , Gaig, Carles , Sabater, Lídia , Santamaría, Joan , Prüß, Harald , Lewerenz, Jan , Irani, Sarosh R. , Mignot, Emmanuel , Titulaer, Maarten J. , Ayzenberg, Ilya , Francillard, Aurélie Méneret Isabelle, Renard, Dimitri , Desestret, Virginie, Capet, Nicolas , Davion, Jean‐Baptiste , Boucher, Julie, Combres, Helene, Rafiq, Marie , Bonneville, Fabrice , Cumin, Marina, Soulages, Antoine , Compoint, Mathilde, Moulin, Maximilien , Berling, Édouard , Garrigues, Eve, Chanson, Marine, Bourg, Veronique , Giordana, Caroline, Benoit, Jeanne , Flabeau, Olivier, Derivoyre, Emmanuelle, Ryckewaert, Gilles, Alberto, Tifanie, Carrière, Nicolas , Mostoufizadehs, Sohrab, Barbay, Mélanie , Bénaiteau, Marie , Sellal, François , Casez, Olivier, Bruel, Cédric , Kalifa, L G, Rusu, Elena Camelia, Demortière, Sarah , Maarouf, Adil, Wang, Adrien , Brasset, Adelaide, Attal, Arthur, Demourant, Céline, Houéto, Jean‐Luc , Brueggemann, Norbert, Dargvainiene, Justina , Oy, Ulrich Hofstadt‐van , Nagel, Michael , Urbanek, Christian, Schroeder, Ina, Schramm, Peter , Tonner, Silke, Seitz, Caspar , Tschernatsch, Marlene , Chung, Ha‐Yeun , Wickel, Jonathan , Schoeberl, Florian, Macher, Stefan , Simabukuro, Mateus Mistieri , Zittel-Dirks, Simone, Wildemann, Brigitte , Kothaj, Ján, Ordás, Carlos , Angstwurm, Klemens , Tomás, Ángela Milán, Bastida, Antonio Martin, Quintas, Sonia , Kimura, Akio , Akira, Takekoshi, Scheller-Nissen, Mette, Hartmann, Christian, Bastiaansen, Danielle, Steenhoven, Robin van, Schwichtenberg, Katia , Yogeshwar, Selina M , Grüter, Thomas , Muñiz-Castrillo, Sergio , Melzer, Nico , Leypoldt, Frank , Pittock, S J , Höftberger, Romana , Howe, Charles L , Irani, Sarosh R , Mignot, Emmanuel , Honnorat, Jérôme , Finke, Carsten , Titulaer, Maarten J , Crijnen, Y S , Heidbreder, Anna , Geis, Christian , Blaabjerg, Morten , Pittock, Sean J. , Graus, Francesc , Dalmau, Josep , Schreiner, Bettina , Honnorat, Jérôme , Méneret, Aurélie , Desestret, Virginie , Boucher, Julie, Zéphir, Hélène , Damier, Philippe , Combres, Hélène, Cumin, Marina, Compoint, Mathilde, Chanson, Marine, Vogrig, Alberto , Casez, Olivier , Kalifa, Laurette, Rusu, Elena Camelia, Carra‐Dallière, Clarisse , Cluse, Florent , Brueggemann, Norbert, Seifert‐Held, Thomas , Villacieros‐Álvarez, Javier , Berger–Sieczkowski, Evelyn , Tambasco, Nicola , Nigro, Pasquale , Iorio, Raffaele , Ono, Yoya , Shimohata, Takayoshi , Bastiaansen, Danielle

Mayo Clinic

Brain | July 12, 2025 | Volume: 149 | Issue: 3 | Pages: 884-896

10.1093/brain/awaf256 | PMID 40650880 Get It

Abstract Anti-IgLON5 disease is an autoimmune encephalitis that presents with a heterogenous clinical phenotype, including sleep disorders, movement abnormalities and bulbar involvement. It is characterized by autoantibodies against IgLON5, 85% association with HLA-DQB1*05:∼ and a brainstem-dominant tauopathy. Cellular and murine models report pathogenic effects of the autoantibodies, and neurodegenerative factors suggest progressive atrophy as a common sequela. However, evidence from in vivo patient data and long-term follow-up is limited, and the degree of progression remains elusive. In this multicentre study, clinical and brain MRI data were collected from 127 patients across 12 countries to investigate the relationships between clinical presentations and the development of distinct brain atrophy patterns. Our data show that most patients develop a complex multisystem phenotype as the disease progresses; however, neuromuscular manifestations rarely emerge at later disease stages. By comparison to healthy controls, this disease presents with severe substructure-specific atrophy, especially affecting the hypothalamus, brainstem, accumbens and basal ganglia, which, in age-independent analyses, show significant ventricular enlargement and also suggest progression of brainstem atrophy over the disease course. Moreover, the focality of atrophy was functionally linked to specific symptoms, with more severe involvement of the basal ganglia in patients with movement disorders, and greater atrophy in the hippocampus and thalamus in patients with cognitive impairment. Taken together, our results provide evidence of distinct atrophy patterns in anti-IgLON5 disease, which closely mirror sites of pathophysiologic processes, including autoantibody binding and tau deposition. Our data emphasize the brainstem as the pathophysiological hub of the disease and provide normative data for the incorporation of atrophy measurements into routine clinical assessments and future treatment studies to monitor disease trajectory and evaluate future treatment strategies.
Multicenter evaluation of blood culture contamination and blood cultures practices in US acute care hospitals: time for standardization
Fabre, Valeria , Hsu, Yea‐Jen , Carroll, Karen C. , Salinas, Alejandra , Abbo, Lilian M. , Bower, Chris , Berry, J. Michael, Degnan, Kathleen, Dhaubhadel, Pragya, Dress, Marci, Feeser, Baevin , Fisher, Mark , Flynn, Cynthia E. , Gettler, Erin , Glasser, Laurel J., Johnson, J. Kristie, Karaba, Sara M. , Kubischta, Alyssa, Landrum, B. Mark, Martinez, Marvin, Mermel, Leonard A. , Pepe, Dana , Qasba, Sonia, Rittmann, Barry , Robinson, Evan D. , Rosa, Rossana , Salinas, Jorge , Shah, Aditya , Schrank, Gregory M. , Spivak, Emily S , Stewart, Kathleen O., Wasylyshyn, Anastasia , Virk, Zunaira, Cosgrove, Sara E. , Abbo, Lilian M , Karaba, Sara M , Fabre, Valeria , Milstone, Aaron M. , Berry, Jennifer, Boyd, Sarah, Diekema, Daniel J. , Ford, Bradley , Glasser, Laurel J., Howard‐Anderson, Jessica , Kim, Justin , Mathers, Amy J. , Moehring, Rebekah W. , O’Horo, John C. , Rodriguez‐Nava, Guillermo , Ryder, Jonathan H. , Shelly, Mark , Talbot, Thomas R. , Schooneveld, Trevor Van , Gadala, Avinash

Mayo Clinic

Journal of Clinical Microbiology | July 11, 2025 | Volume: 63 | Issue: 8 | Pages: No page available

10.1128/jcm.00530-25 | PMID 40643261 Get It

ABSTRACT Clinical and Laboratory Standards Institute (CLSI) recommends a blood culture contamination (BCC) threshold of <3%, with ≤1% considered optimal. However, there is not a standardized definition of BCC, and the effect of multiple definitions on BCC rates or what definitions laboratories use remain unknown. We surveyed 52 hospitals and analyzed 362,078 blood cultures (BCx) collected 1 September 2019 to 31 August 2021 from 62 intensive care units (ICUs) and 231 wards from 48 of these hospitals. We calculated and compared BCC rates using the College of American Pathologists (CAP) or CLSI criteria (both utilize a limited number of skin commensals to define BCC) and the comprehensive National Healthcare Safety Network (NHSN) commensal list. We characterized factors associated with BCC and related outcomes (central-line associated bloodstream infection [CLABSI] and vancomycin use). BCC, BCx positivity, and single BCx rates were monitored by 100%, 39%, and 21% of hospitals, respectively. Hospitals used CAP (65%), CLSI (17%), and NHSN (17%) criteria to define BCC. Mean BCC rate by CAP (CAP-BCC) was 1.38% for ICUs and 0.96% for wards. BCC rates remained similar by CLSI criteria but increased when using NHSN list. Sharing BCC data outside of the laboratory, measuring additional BCx quality indicators, and limiting central catheter-drawn BCx were associated with lower BCC rates. BCC was associated with higher CLABSI rates in ICUs. This study demonstrated variability in laboratory practices and opportunities to optimize BCx stewardship. IMPORTANCE Blood culture contamination (BCC) is associated with patient harm and unnecessary use of healthcare resources. BCC thresholds have been established; however, multiple BCC definitions exist. There is limited data on how BCC rates differ depending on the BCC definition used, what definitions laboratories most commonly use, or their approach to other blood cultures (BCx) quality indicators such as single rates or BCx positivity. A cross-sectional multicenter survey and analysis of BCx data from intensive care unit and wards revealed that most laboratories did not track single BCx or BCx positivity rates and that there was variability in how BCC was defined. Additionally, BCC rates were influenced by the definition used. BCC was associated with increased central-line associated bloodstream infection rates.
Mucinous cystic neoplasm in men: a comparative study
Dundar, Bilge , Adsay, Volkan , Allende, Daniela , Jenkins, Sarah M. , Pai, Rish K. , Passow, Marie R. , Reid, Michelle D. , Westerhoff, Maria , Zen, Yoh , Graham, Rondell P. , Adsay, N Volkan , Allende, Daniela S , Graham, Rondell P , Reid, Michelle D

Mayo Clinic

Histopathology | July 11, 2025 | Volume: 87 | Issue: 4 | Pages: 548-556

10.1111/his.15511 | PMID 40641220 Get It

AimsMucinous cystic neoplasms (MCN) are defined by the presence of an ovarian‐type stroma (OTS). Once ovarian stroma has become a requirement for the diagnosis of MCNs, studies using this criterion have disclosed that MCNs are seen almost exclusively (97%) in women. The occurrence of MCNs (with ovarian stroma) in men is exceedingly rare and raises questions about the origin of OTS and the role of hormones in tumourigenesis. This study aims to investigate the clinical and histopathological features of pancreatic or hepatic MCNs in men.Methods and resultsWe examined the MCN cases in men and compared them with age‐matched women. We further investigated MCN in premenopausal and postmenopausal women to explore the impact of hormonal status.The stromal cellularity tended to be lower in men as compared to women; however, limited numbers prevented statistical significance. Clinical presentation, tumour location, body mass index and cyst complexity were similar between men and age‐matched women, similarly in pre‐ and postmenopausal woman groups. All MCN cases, regardless of gender or hormonal status, showed OTS with positivity for oestrogen receptor (ER), androgen receptor (AR) and SF‐1 immunostains. Additionally, the presence of AR and ER‐beta in lining epithelial cells, in addition to the stromal cells, raised the probability for a potential role for local hormonal signalling in the pathogenesis of these tumours.ConclusionsMCNs in men had overlapping histopathologic and immunohistochemical profiles with those in women, regardless of menopausal status.
Ophthalmic Knowledge Assessment Program Scores and Written Qualifying Examination Performance
Thanitcul, Chanon, Schnabel, Sarah , Bartley, George B., Lee, Andrew G., Crump, Hally, Fajardo, Dale , Peters, Kathryn F., Wilson, Beth, Peters, Kathryn, Srikumaran, Divya S.

Mayo Clinic

JAMA Ophthalmology | July 10, 2025 | Volume: 143 | Issue: 8 | Pages: 678

10.1001/jamaophthalmol.2025.1933 | PMID 40638098 Get It

ImportanceThe Ophthalmic Knowledge Assessment Program (OKAP) has been widely used to determine readiness to take the high-stakes Written Qualifying Examination (WQE). However, it is unclear how well OKAP performance can predict WQE outcomes.ObjectiveTo examine the association between the OKAP and WQE nationally.Design, Setting, and ParticipantsThis was a retrospective cohort study conducted from 2017 to 2022. This national data analysis included residents from ophthalmology residency programs in the US. Study data were analyzed June 2023 to December 2024.ExposuresOKAP and WQE data.Main Outcomes and MeasuresThe national OKAP examination data and the WQE data were matched. Candidates who had complete data for the OKAP during postgraduate year (PGY) 2, 3, and 4 and completed the WQE were included in the study. Two-sample t tests, logistic regression analysis, receiver operating characteristic curves, and confusion matrix were used to examine the association of various test scores (PGY-2 OKAP, PGY-3 OKAP, PGY-4 OKAP, minimum OKAP, maximum OKAP, average OKAP) as predictors for WQE outcomes (pass or fail). Multiple logistic regression analyses were also used to assess the association of gender, time since graduation, program size, and WQE pass/fail outcomes.ResultsA total of 1597 residents (907 male [56.8%]) from 117 residency programs were included in this study. First-time pass rate of the WQE was 89% (1418 of 1597 residents). OKAP scores, particularly average OKAP, maximum OKAP, and PGY-4 OKAP scores (all had area under the curve = 0.88), were the most useful predictor of WQE outcomes. PGY-4 OKAP scores were used for the rest of the analysis for simplicity. A PGY-4 OKAP scaled score of 550 corresponded to 94% of candidates passing the WQE. Using PGY-4 OKAP scores to predict passing/failing, the WQE had 90.7% accuracy. Gender (odds ratio [OR], 1.50; 95% CI, 1.01-2.26; P = .048), program size (OR, 1.55; 95% CI, 0.98-2.41; P = .06), and time since residency graduation (OR, 1.00; 95% CI, 1.00-1.00; P = .14) were not included in the logistic regression model investigating the association of PGY-4 OKAP scores with the likelihood of passing the WQE.Conclusions and RelevanceResults suggest that OKAP examination scores were associated with passing the WQE after adjusting for program size, gender, and time since residency graduation. Further analyses may be warranted to predict failing the WQE so that potential interventions can be attempted.